Progenics Pharma (PGNX) Reports Q4 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), versus ($0.10) reported last year. Revenue for the quarter came in at $4.65 million, versus $5.1 million reported last year.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- Pursuit Attractions and Hospitality, Inc. (PRSU) Misses Q3 EPS by 601c ; Offers Guidance
- Prospect Capital (PSEC) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
